The Cambridge-based pharmaceutical giant is seeking to add the biotech company, which has been pursuing treatments for type 1 diabetes, to its portfolio.
↧
The Cambridge-based pharmaceutical giant is seeking to add the biotech company, which has been pursuing treatments for type 1 diabetes, to its portfolio.